The B2M Knockout Ca Ski Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Ca Ski human cervical carcinoma cell line, designed for loss-of-function studies of the B2M gene. This product enables the investigation of beta-2-microglobulin (B2M) deficiency, a critical component of major histocompatibility complex (MHC) class I molecules. Through CRISPR/Cas9-mediated gene disruption, the polyclonal pool harbors a heterogeneous collection of B2M mutations, leading to abrogation of B2M protein expression and consequent elimination of surface MHC class I complexes. This model supports functional analyses of antigen presentation and immune recognition in a genetically diverse knockout context.
The Ca Ski cell line was established from a cervical epidermoid carcinoma metastatic to the small intestine and harbors integrated human papillomavirus type 16 (HPV-16) sequences. As an adherent epithelial cell line, Ca Ski recapitulates key features of HPV-driven cervical squamous cell carcinoma, including constitutive expression of viral oncogenes E6 and E7. These oncoproteins interfere with tumor suppressor pathways, promoting genomic instability and aberrant proliferation. The presence of HPV-16 integration provides a clinically relevant backdrop for studying immune evasion mechanisms in cervical cancer, particularly those involving MHC class I downregulation.
B2M, the invariant light chain of MHC class I molecules, is essential for assembly, peptide loading, and surface transport. It interacts with MHC class I heavy chains (HLA-A, B, C) and the peptide-loading complex components calnexin, calreticulin, tapasin, and ERp57. B2M also binds HFE, connecting MHC class I to iron homeostasis via hepcidin regulation. Loss of B2M disrupts these interactions, preventing CD8+ T cell recognition of peptide?CMHC class I complexes and impairing TCR engagement. B2M expression is regulated by IFN-??, TNF-??, type I interferons, and IL-1, which transcriptionally activate MHC class I components.
In the Ca Ski cervical cancer context, B2M disruption models the immune evasion phenotype frequently observed in HPV-associated malignancies, where MHC class I downregulation facilitates escape from CD8+ T cell-mediated surveillance. This knockout population enables dissection of how viral oncoproteins cooperate with genetic lesions in antigen presentation machinery to promote tumor progression. The loss of B2M also offers a unique opportunity to explore iron metabolism dysregulation in cancer, as the HFE?CB2M?CMHC class I axis influences hepcidin signaling and cellular iron handling. Researchers can thus interrogate the intersection of immune escape and metabolic adaptation in a genetically defined system.
Typical applications include flow cytometry to quantify surface MHC class I loss, western blotting and RT-qPCR for confirming B2M ablation, and T cell-mediated cytotoxicity assays to evaluate immune recognition. The model supports RNA-seq analyses under IFN-?? stimulation to map transcriptional networks governed by MHC class I signaling and serves as a platform for screening immunotherapeutic agents designed to restore antigen presentation. Further applications involve iron uptake assays to probe HFE-dependent regulatory mechanisms. To inquire about availability, customization, or additional characterization data for this product, please contact Ascent Research.
